Group Profile
Chipscreen Biosciences is an innovative drug company driven by core technologies with globally competitive pipelines. As a pioneer in drug innovation & development in China, adhering to the concept of "Constant Innovation for Life", we focus on developing revolutionary innovative drugs with new mechanisms of action, to address patients' pressing clinical needs. Our complete industry chain that covers early exploratory discovery through commercialization allows us to provide innovative Chinese drugs for patients worldwide.
With a global development strategy based on early-stage research in China, Chipscreen Biosciences has leveraged the top scientists and teams with extensive experience in related fields from the Shenzhen Small Molecule Early R&D Center and Chengdu Small Molecule Early R&D Center to create an integrated technology platform based on AI-driven design and chemical genomics, which spanned the whole process from basic science to clinical translation. We have successfully developed first-in-class and best-in-class innovative drugs. Currently, we have marketed two drugs for three indications in Mainland China, two indications in Japan, and one indication in Taiwan, China. In addition, we have launched a number of R&D projects with differentiated advantages and global competitiveness in the five major areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals.
Chipscreen Biosciences has formed a global industrial layout consisting of Shenzhen Head Office/R&D Center/GMP production base, Chengdu Regional Head Office/R&D Center/GMP production base, Beijing Branch, Shanghai Branch, and Chipscreen Biosciences (USA) Co., Ltd. Meanwhile, as one of the first batches of national "innovative drug incubation bases" and national high-tech enterprises, Chipscreen Biosciences has independently undertaken many national "863" plans and national major science and technology projects, such as "10th five-year plan", "11th five-year plan", "12th five-year plan" and "13th five-year plan", and National Science and Technology primary Project for Innovative Drug Development. We have filed over 660 invention patents in China and worldwide, with over 180 granted.
Shenzhen Chipscreen Pharmaceutical Ltd.
Shenzhen Chipscreen Pharmaceutical Ltd., incorporated on Mar. 16, 2017, is located at No. 21, Jinxiu East Road, Kengzi Street, Pingshan New District, Shenzhen. A wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd., it was formerly the Pingshan manufacturing base of Chipscreen Biosciences, and is now the industrialization base for the Company’s first original anti-tumor drug, Chidamide. The subsidiary consists of the Group’s innovative drug CMC technology transfer center, an oncologic API and formulation workshop, a quality management center, and other production-related supporting facilities.
Chengdu Chipscreen Pharmaceutical Ltd.
Chengdu Chipscreen Pharmaceutical Ltd., incorporated on Apr. 28, 2014, is a wholly-owned subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. Consisting of two sites, the Innovative Drug Manufacturing Base and the Innovative Drug R&D Center and Regional Headquarters, Chengdu Chipscreen Pharmaceutical plays a pivotal role in the regional development of the Group.
The Innovative Drug Manufacturing：Base is located at No. 298, Kangqiang Yi Road, West High-tech Zone, Chengdu. The facilities here include oncology and non-oncology API and oral solid formulation workshops, which are designed in accordance with GMP standards of the US, EU and China. In order to fully meet demand for pilot scale testing of innovative drugs, preparation of clinical samples and production of commercial batches, new facilities including workshops for oncologic and non-oncologic injections and antibody drugs are under construction.
The Innovative Drug R&D Center and Regional Headquarters：is located at No. 18, Xintongnan Yi Road, Xinchuan Science and Technology Park, South High-tech Zone, Chengdu. A vital part of the Group’s R&D system, the Innovative Drug R&D Center will work with and complement the Early Research & Development Center (Shenzhen) in building product pipelines and supporting clinical research needed for the company’s sustainable development.
Beijing Branch of Shenzhen Chipscreen Biosciences Co., Ltd.,( Clinical Research Center of Shenzhen Chipscreen Biosciences Co., Ltd.,)
located in Chaoyang District, Beijing, is a Clinical Research and Operations Center, functioning as clinical project managements and supporting for drug registrations.
Shanghai Branch of Shenzhen Chipscreen Biosciences Co., Ltd., (Business Center of Shenzhen Chipscreen Biosciences Co., Ltd., )
located in Putuo District, Shanghai, is the Group’s marketing center, as well as the base for product strategy development and business expansion.
Chipscreen Biosciences (United States) Limited
Chipscreen Biosciences (United States) Limited was incorporated on Oct. 16, 2020. Registered in Newark, Delaware with its offices located in Somerset, New Jersey, Chipscreen Biosciences (United States) Limited is a wholly-owned subsidiary of Shenzhen Chipscreen Biotechnology Co., Ltd. that serves as the international clinical development center of the Company, assisting with Chipscreen’s globalization.
Chengdu Chipscreen Newway Biosciences Co., Ltd.
Chengdu Chipscreen Newway Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Newway") is an innovative biotechnology enterprise committed to the development of large molecules and other novel therapeutic technologies under Chipscreen Biosciences. Chipscreen Newway specializes in novel therapeutic methods and technologies including but not limited to nucleic acid drugs and large molecules represented by antibodies and Antibody–Drug Conjugates (ADC). We are dedicated to developing drugs with novel mechanisms of action that meet clinical needs in disease areas, such as tumors and autoimmune diseases, to provide patients with innovative and leading therapeutic methods and options.
